Sign In
Buy GALT
$2.35
-0.0700 (-2.89%)
At Close: Jun 03, 2026
Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
01:55pm, Tuesday, 05'th Oct 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's managemen
Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
09:00am, Thursday, 09'th Sep 2021
NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's manageme
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has rec
GALT Stock Increased 25%: Why It Happened
05:27pm, Saturday, 10'th Jul 2021
The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased 25% yesterday. This is why it happened.
GALT Stock: The Big Trial News That Has Galectin Therapeutics Soaring
02:55pm, Friday, 09'th Jul 2021
Today, a key announcement of some positive clinical trial data has sent investors in Galectin and GALT stock on a nice ride. The post GALT Stock: The Big Trial News That Has Galectin Therapeutics Soar
Why Galectin Is Soaring And Sigilon Is Sinking Today
09:58am, Friday, 09'th Jul 2021
Galectin Therapeutics Inc. (NASDAQ: GALT) and Sigilon Therapeutics, Inc. (NASDAQ: SGTX) are among the biggest movers among biopharma stocks in early trading Friday. Galectin Spikes On Positive Data Fo
Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer
09:25am, Friday, 09'th Jul 2021
Galectin Therapeutics Inc (NASDAQ: GALT) has announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (
Galectin Therapeutics Stock Increases Over 40% Pre-Market: Why It Happened
09:12am, Friday, 09'th Jul 2021
The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by over 40% pre-market. This is why it happened.
8 ‘Must Watch' Penny Stocks For Your July 2021 List
09:03am, Friday, 09'th Jul 2021
Are these 'must watch' penny stocks on your radar? The post 8 ‘Must Watch' Penny Stocks For Your July 2021 List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NORCROSS, Ga., July 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Earle A. Chiles Research Institu
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update
08:00am, Monday, 17'th May 2021
Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials
Galectin Therapeutics to Present at 4th Global NASH Congress
09:28am, Tuesday, 27'th Apr 2021
NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D
Galectin Therapeutics: The Galectin Signature - Signed, Sealed, And About To Be Delivered
06:07pm, Friday, 16'th Apr 2021
Recent immuno-oncology publications further confirm the Galectin Signature in cancer immunotherapy. In a rare and important combination of clinical effects, belapectin, Galectin's galectin-3 inhibitor
GALT Stock: Over 25% Increase Pre-Market Explanation
07:53am, Wednesday, 14'th Apr 2021
The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by over 25% pre-market. This is why it happened.
Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone Combination therapy with belapectin suggests a better obje
